Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYCOPHENOLATE SODIUM vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Prophylaxis of organ rejection in renal transplant patients receiving cyclosporine and corticosteroids,Prophylaxis of organ rejection in cardiac transplant patients (off-label),Prophylaxis of organ rejection in hepatic transplant patients (off-label),Treatment of lupus nephritis (off-label)
Mild to moderate pain,Fever
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Mycophenolate sodium is a prodrug that is rapidly hydrolyzed in the gastrointestinal tract to the active metabolite mycophenolic acid (MPA). MPA is primarily metabolized by uridine diphosphate-glucuronosyltransferase (UGT) 1A9 to the inactive phenolic glucuronide (MPAG). A minor acyl glucuronide metabolite is also formed. MPAG is excreted in the urine and can be deconjugated back to MPA via enterohepatic recirculation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Mycophenolic acid is 97% bound to serum albumin. The glucuronide metabolite (MPAG) is 82% bound.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
The apparent volume of distribution of mycophenolic acid is approximately 3.6 L/kg, indicating extensive tissue distribution. This large Vd reflects high tissue binding and distribution into extravascular spaces.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
The oral bioavailability of mycophenolate sodium enteric-coated tablets is approximately 72% relative to intravenous mycophenolate mofetil. Food reduces peak concentration (Cmax) by 30-50% but does not significantly affect total area under the curve (AUC).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR 15-29 m L/min/1.73 m2: do not exceed 720 mg orally twice daily. For GFR <15 m L/min/1.73 m2: no data; use with caution. No adjustment for GFR >=30 m L/min/1.73 m2.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No specific dose adjustment guidelines for Child-Pugh class A, B, or C. Use with caution in severe hepatic impairment due to limited data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Approved for pediatric renal transplant patients >=2 years: 400 mg/m2 orally twice daily (up to a maximum of 720 mg twice daily). For bone marrow transplant patients >=2 years: 400 mg/m2 orally twice daily, starting 24 hours after graft infusion.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment recommended; elderly patients may have increased risk of adverse effects such as gastrointestinal hemorrhage and infections. Use the lowest effective dose and monitor renal function closely.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Increased risk of congenital malformations and first-trimester pregnancy loss when used during pregnancy. Females of reproductive potential must be counseled about pregnancy prevention and planning. Mycophenolate can cause fetal harm when administered to a pregnant woman. Use is contraindicated in women of childbearing potential who are not using highly effective contraception.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Immunosuppression: Increased susceptibility to infections, including opportunistic infections and reactivation of latent viruses (e.g., CMV, BK virus).,Lymphoproliferative disorders: Increased risk of post-transplant lymphoproliferative disorder (PTLD) and other malignancies.,Pregnancy: Associated with first-trimester pregnancy loss and congenital malformations; contraception counseling required.,Gastrointestinal events: Severe GI bleeding, perforation, and ulceration; monitor for symptoms.,Neutropenia: Can cause severe neutropenia; monitor complete blood counts regularly.,Vaccinations: Live vaccines should not be given during treatment; influenza vaccination may be less effective.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to mycophenolate sodium, mycophenolic acid, or any component of the formulation,Women of childbearing potential not using highly effective contraception,Pregnancy (unless no suitable alternative immunosuppressant is available)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Take on an empty stomach (1 hour before or 2 hours after meals) to minimize variability. Avoid grapefruit juice (may increase mycophenolate exposure). No specific dietary restrictions other than consistent timing relative to meals. High-fat meals reduce Cmax and AUC; administer consistently with or without food.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of oligohydramnios, intrauterine growth restriction, and preterm birth. Use is contraindicated in pregnancy unless no alternative.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Enters breast milk; M/P ratio not established. Potential for serious adverse effects in nursing infants (e.g., immunosuppression, gastrointestinal disturbances). Contraindicated during breastfeeding.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pharmacokinetic changes (increased clearance, decreased absorption) may require higher doses to maintain therapeutic levels; therapeutic drug monitoring recommended. Postpartum doses may need reduction due to changed pharmacokinetics.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Monitor CBC weekly during first month, then biweekly for second and third months, then monthly for first year. Consider therapeutic drug monitoring (AUC 30-60 mg·h/L) to optimize dosing and reduce toxicity. Delayed-release formulation (Myfortic) must not be crushed or chewed. Avoid concurrent antacids or bile acid sequestrants. Dose reduction required in renal impairment (e GFR <50 m L/min). Estimate using ideal body weight. Taper when discontinuing to avoid graft rejection.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not stop or change dose without consulting your transplant team.,Swallow delayed-release tablets whole; do not crush, chew, or cut them.,Use reliable contraception before, during, and for 6 weeks after treatment for females; males should use condoms during and for 90 days after treatment.,Avoid live vaccines (e.g., MMR, varicella) and close contact with recently vaccinated individuals.,Report signs of infection (fever, sore throat, chills), unexplained bruising/bleeding, or GI symptoms (nausea, diarrhea, abdominal pain).,Take on an empty stomach (1 hour before or 2 hours after meals) for consistent absorption.,Avoid grapefruit juice as it may alter drug levels.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYCOPHENOLATE SODIUM vs ACEPHEN, answered by our medical review team.
MYCOPHENOLATE SODIUM is a Immunosuppressant that works by Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYCOPHENOLATE SODIUM and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYCOPHENOLATE SODIUM is: 720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYCOPHENOLATE SODIUM and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYCOPHENOLATE SODIUM is classified as Category C. First trimester: High risk of structural malformations (e.g., cleft lip/palate, microtia, congenital heart defects) and spontaneous abortion. Second and third trimesters: Risk of o. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.